Plain-English translation of NCT07650149 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing tirzepatide, a newer injectable medication that helps with weight loss by working on two hormones that control hunger and blood sugar. The researchers want to understand why some people do very well on this medication while others struggle — and they think the answer may lie in your genes, your gut bacteria, and your everyday habits and behaviors.
Weight loss medications don't work the same way for everyone, and some people have trouble sticking with them or tolerating them. This study aims to figure out which personal factors — your genetic makeup, your microbiome (the bacteria in your gut), and your lifestyle — predict whether this medication will work well for you and whether you'll be able to stay on it long-term.
You likely qualify if…
You likely don't qualify if…
You would receive tirzepatide injections as part of your weight loss treatment. The researchers would collect blood and stool samples to study your genes and gut bacteria, and they would ask you questions about your eating habits, exercise, and daily life. The study involves 200 people total, and you would be monitored to see how well you tolerate the medication, how consistently you use it, and how much weight you lose.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
Poland
Sponsor
Jan Kochanowski University
Collaborators
LUX MED Group
Enrollment target
~200 participants
Started
May 2026
Primary completion
May 2027
Age range
18 Years – 60 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zbigniew Siudak PI, MD, PhD
Jan Kochanowski University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.